ANSWER: B

Rationale:

Metoprolol is metabolized predominantly by CYP2D6 (cytochrome P450 2D6) to its inactive alpha-hydroxymetoprolol metabolite. Terbinafine is a potent mechanism-based inhibitor of CYP2D6 that covalently and irreversibly inactivates the enzyme; within days of initiating terbinafine, CYP2D6 activity is substantially reduced, metoprolol clearance falls, and plasma metoprolol concentrations rise significantly. The clinical consequence is exaggerated beta-1 adrenoceptor blockade — in this patient manifesting as symptomatic bradycardia (heart rate 46 from a baseline of 62–68) and orthostatic dizziness from reduced cardiac output and blunted compensatory tachycardia. This interaction is well established and clinically important given metoprolol's narrow beta-blockade window. Management requires either reducing the metoprolol dose, withholding it temporarily, or using an alternative antifungal. The bradycardia would not resolve until terbinafine is stopped and newly synthesized CYP2D6 enzyme accumulates over subsequent weeks.

• Option A: Option A is incorrect because terbinafine does not produce a Jarisch-Herxheimer-like systemic reaction from dermatophyte die-off; this phenomenon is associated with spirochetal diseases (syphilis, Lyme), not with superficial fungal infections.
• Option C: Option C is incorrect because terbinafine does not inhibit hepatic blood flow or reduce hepatic extraction ratio; the relevant pharmacokinetic mechanism is CYP2D6 inhibition, and nortriptyline's alpha-1 blockade at therapeutic concentrations does not produce the bradycardia described.
• Option D: Option D is incorrect because terbinafine's primary CYP interaction is CYP2D6 inhibition, not CYP3A4 inhibition, and extended-release formulation dissolution is not a CYP3A4-dependent process; matrix dissolution is physical, not enzymatic.
• Option E: Option E is incorrect because terbinafine has well-documented pharmacokinetic interactions with CYP2D6 substrates including metoprolol, and the drug interaction — not underlying conduction disease — is the direct pharmacological explanation for the new-onset bradycardia in temporal relation to terbinafine initiation.

ANSWER: D

Rationale:

This question illustrates that terbinafine's CYP2D6 inhibition affects all CYP2D6 substrates concurrently, not just the drug that produced the initial symptom. Nortriptyline, like metoprolol, is metabolized substantially by CYP2D6; terbinafine-induced CYP2D6 inhibition reduces nortriptyline clearance and elevates its plasma concentrations. Nortriptyline at elevated concentrations produces classical tricyclic antidepressant toxicity driven by its potent muscarinic receptor (anticholinergic) activity: urinary retention from detrusor and internal sphincter dysfunction, dry mouth from reduced salivary gland secretion, blurred vision from ciliary muscle paralysis and mydriasis, and tachycardia from vagal (muscarinic) blockade at the sinoatrial node. Once metoprolol was held and beta-blockade removed, the tachycardia component of nortriptyline toxicity — previously partially masked by metoprolol's rate-limiting effect — became apparent. This case illustrates why prescribers must review all CYP2D6 substrates when terbinafine is initiated, not only the drug with the most immediately obvious interaction.

• Option A: Option A is incorrect because metoprolol rebound adrenergic activation is not the explanation; urinary retention and dry mouth are not features of adrenergic rebound, which characteristically produces hypertension, tachycardia, and angina but not anticholinergic features.
• Option B: Option B is incorrect because terbinafine does not induce CYP1A2 in a clinically meaningful way, and nortriptyline is not metabolized to a cardiotoxic catecholamine metabolite through CYP1A2 induction; this mechanism is fabricated.
• Option C: Option C is incorrect because the clinical features described — urinary retention, dry mouth, blurred vision, tachycardia — constitute an anticholinergic toxidrome, not a serotonin toxicity syndrome; serotonin syndrome characteristically produces agitation, clonus, hyperthermia, and diaphoresis, which are absent here.
• Option E: Option E is incorrect because nortriptyline's sodium channel blockade does not produce anticholinergic-like features through an indirect mechanism following beta-blocker withdrawal; the symptoms are directly attributable to elevated nortriptyline plasma concentrations producing muscarinic receptor blockade.

ANSWER: A

Rationale:

The correct management requires addressing both the pharmacokinetic cause and its clinical consequences. Terbinafine should be discontinued because it is the source of CYP2D6 inhibition driving accumulation of both metoprolol and nortriptyline. Nortriptyline dose should be reduced, since even after terbinafine is stopped, plasma nortriptyline concentrations will remain elevated for a period while CYP2D6 activity is gradually restored through new enzyme synthesis; failing to reduce the dose would perpetuate toxicity. Metoprolol can be restarted at a reduced dose once anticholinergic symptoms resolve and nortriptyline levels have begun to normalize. Critically, the patient must understand that terbinafine's mechanism-based CYP2D6 inhibition is irreversible and recovery depends on de novo enzyme synthesis, which takes weeks — drug concentrations do not normalize immediately after stopping terbinafine, and monitoring must continue well beyond discontinuation. An alternative antifungal with a better interaction profile can be considered once the acute toxicity is managed.

• Option B: Option B is incorrect because adding rifampin to induce CYP2D6 is not a clinically appropriate or established strategy for reversing mechanism-based CYP2D6 inhibition; rifampin is a CYP inducer but acts primarily on CYP3A4 and CYP2C enzymes, not CYP2D6, and this approach would introduce additional pharmacokinetic complexity without reliably restoring CYP2D6 activity.
• Option C: Option C is incorrect because continuing terbinafine maintains ongoing CYP2D6 inhibition and perpetuates toxicity; physostigmine is used in acute severe anticholinergic crisis in monitored settings but is not appropriate outpatient management, and the statement that nortriptyline levels normalize within 24 hours of CYP2D6 activity returning is incorrect — recovery takes weeks.
• Option D: Option D is incorrect because switching from terbinafine to itraconazole does not immediately restore CYP2D6 function; the mechanism-based inhibition by terbinafine leaves CYP2D6 irreversibly inactivated, and enzyme activity recovers through new synthesis over weeks regardless of whether terbinafine is replaced by another drug.
• Option E: Option E is incorrect because increasing nortriptyline dose in a patient experiencing nortriptyline toxicity would worsen the anticholinergic syndrome; the correct approach is dose reduction, and continuing terbinafine would perpetuate CYP2D6 inhibition.

ANSWER: E

Rationale:

Itraconazole is an effective systemic antifungal for dermatophyte onychomycosis caused by Trichophyton rubrum and is an appropriate alternative to terbinafine for this indication. Critically, itraconazole does not inhibit CYP2D6, so it avoids the pharmacokinetic interactions that caused metoprolol accumulation and nortriptyline toxicity in this patient. However, itraconazole is itself a potent inhibitor of CYP3A4 (and P-glycoprotein), which means it carries its own drug interaction burden through a different metabolic pathway. Before initiating itraconazole in any patient with polypharmacy, the prescriber must review the full medication list for CYP3A4 substrates — including statins (particularly simvastatin and lovastatin, which carry risk of rhabdomyolysis from CYP3A4 inhibition), calcium channel blockers, immunosuppressants, and many others. In this specific patient, metoprolol and nortriptyline are not clinically relevant CYP3A4 substrates, so itraconazole would avoid the prior interactions while providing effective treatment.

• Option A: Option A is incorrect because griseofulvin is a CYP3A4 and CYP1A2 inducer, not a drug free of CYP interactions; it would reduce plasma concentrations of CYP3A4 substrates and potentially interact with nortriptyline's metabolism, and it has poor efficacy for onychomycosis with required treatment courses up to 18 months.
• Option B: Option B is incorrect because fluconazole is not the established first-line or highest-cure-rate agent for dermatophyte onychomycosis; terbinafine and itraconazole are the preferred systemic antifungals for this indication, and fluconazole is used off-label with lower cure rates.
• Option C: Option C is incorrect because terbinafine's mechanism-based CYP2D6 inhibition is not dose-proportionally reducible to a safe threshold; even at 125 mg daily, mechanism-based inhibition progressively inactivates CYP2D6 enzyme over time, and a lower starting dose does not guarantee a clinically safe level of inhibition for drugs with narrow therapeutic indices like metoprolol and nortriptyline.
• Option D: Option D is incorrect because topical antifungal therapy is not effective for established onychomycosis; the infection involves the nail matrix and nail bed, which topical agents cannot penetrate in therapeutic concentrations, and this patient has a confirmed indication for systemic therapy.

ANSWER: C

Rationale:

Flucytosine earns its place in the combination induction regimen through two complementary properties. First, its pharmacokinetic profile enables effective CNS delivery: flucytosine is hydrophilic, has minimal plasma protein binding of approximately 4%, and a volume of distribution approximating total body water (approximately 0.6 L/kg); these properties allow it to equilibrate freely across the blood-brain barrier, achieving CSF concentrations that are 70 to 85% of concurrent plasma concentrations — one of the highest CSF penetration ratios of any antifungal agent. Second, its mechanism is pharmacodynamically complementary to amphotericin B: intracellular flucytosine is converted via cytosine deaminase to 5-fluorouracil (5-FU), which inhibits thymidylate synthase via FdUMP (blocking DNA synthesis) and is incorporated into RNA as FUTP (disrupting RNA function) — mechanisms entirely distinct from amphotericin B's membrane disruption. Amphotericin B also enhances flucytosine uptake by increasing membrane permeability, contributing to synergy. Randomized clinical trials including the ACTA (Advancing Cryptococcal Meningitis Treatment for Africa) trial confirm that this combination achieves superior early fungicidal activity (faster CSF sterilization) and improved 10-week survival compared to amphotericin B monotherapy.

• Option A: Option A is incorrect because flucytosine does not inhibit CYP51 (lanosterol demethylase); that is the mechanism of azole antifungals. Flucytosine acts as an antimetabolite through the purine/pyrimidine synthesis pathway, not through ergosterol biosynthesis.
• Option B: Option B is incorrect because while flucytosine does penetrate aqueous compartments well, the justification for its inclusion in cryptococcal meningitis induction is not periventricular white matter distribution or protection against extracranial dissemination; the rationale is CSF penetration and antimetabolite activity at the primary site of infection.
• Option D: Option D is incorrect because flucytosine's role in induction therapy is active fungicidal activity alongside amphotericin B, not prophylactic resistance prevention for future fluconazole consolidation; this misrepresents its pharmacological contribution.
• Option E: Option E is incorrect because flucytosine does not protect against amphotericin B nephrotoxicity through renal tubular competitive inhibition; the co-administration of these two drugs actually requires careful renal monitoring because amphotericin B-induced nephrotoxicity reduces flucytosine renal clearance, raising flucytosine concentrations and myelosuppression risk.

ANSWER: A

Rationale:

When renal function is changing rapidly — as in amphotericin B-induced nephrotoxicity with creatinine doubling from 0.9 to 1.8 mg/dL over six days — standard creatinine-based dose adjustment tables are unreliable for flucytosine dosing. These tables estimate clearance from a static creatinine value that reflects the average renal function over the preceding 24 to 48 hours. In actively evolving nephrotoxicity, today's creatinine underestimates how impaired clearance will be by tomorrow, meaning a dose calculated from today's value may still be excessive. TDM provides a direct measurement of actual drug exposure that is independent of creatinine estimation: the 2-hour post-dose peak should be within 25 to 50 mg/L (some protocols target 40 to 60 mg/L for CNS infections), and the trough must remain below 100 mg/L to prevent concentration-dependent myelosuppression. This principle is explicitly recommended in published guidelines for flucytosine management when renal function is fluctuating.

• Option B: Option B is incorrect because proportional dose reduction based on creatinine doubling, without measuring drug levels, does not confirm whether the adjusted dose achieves the therapeutic target; a mechanical 50% reduction may still leave concentrations above the toxic threshold or below the therapeutic window, and TDM is more reliable.
• Option C: Option C is incorrect because flucytosine should not be reflexively discontinued at any creatinine rise; TDM-guided dose adjustment allows safe continuation with appropriate monitoring, and removing flucytosine eliminates its proven survival benefit.
• Option D: Option D is incorrect because amphotericin B nephrotoxicity involves both tubulotoxic and vasoconstriction-mediated GFR reduction; in practice, GFR falls during amphotericin B nephrotoxicity and flucytosine renal clearance is directly impaired — the distinction between tubulotoxicity and GFR reduction does not protect flucytosine clearance.
• Option E: Option E is incorrect because flucytosine's oral bioavailability exceeds 90%, making the oral and intravenous routes pharmacokinetically interchangeable; intravenous administration does not bypass gut bacterial 5-FU generation, as flucytosine distributes to the gastrointestinal tract regardless of the route of administration.

ANSWER: E

Rationale:

The 2-hour post-dose flucytosine peak of 118 mg/L directly exceeds the established toxic threshold of 100 mg/L above which concentration-dependent myelosuppression risk increases sharply. Myelosuppression arises because gut bacteria convert flucytosine to 5-fluorouracil (5-FU) in the gastrointestinal tract; at elevated plasma flucytosine concentrations, sufficient systemic 5-FU is generated and absorbed to suppress rapidly dividing bone marrow progenitor cells, producing the pancytopenia observed on day 10. The worsening renal function (creatinine now 2.6 mg/dL) has further reduced flucytosine clearance, driving the toxic accumulation. Management requires reducing or withholding flucytosine to bring concentrations within the therapeutic window, then resuming at an adjusted dose or interval guided by repeat TDM. Amphotericin B should continue uninterrupted because its direct bone marrow toxicity is not a recognized primary adverse effect — its toxicities are nephrotoxicity and infusion reactions — and removing it would eliminate the proven fungicidal combination that is producing neurological improvement. Twice-weekly CBC monitoring throughout flucytosine therapy exists precisely to detect this scenario early.

• Option A: Option A is incorrect because amphotericin B (liposomal formulation in particular) does not commonly produce direct bone marrow suppression as a primary toxicity; the elevated flucytosine level at 118 mg/L provides a direct pharmacokinetic explanation that should not be dismissed in favor of an amphotericin B-related diagnosis that lacks supporting evidence.
• Option B: Option B is incorrect because IRIS typically produces inflammatory rather than myelosuppressive features — fever, worsening meningitis, lymphadenopathy — not pancytopenia, and a flucytosine level 18 mg/L above the toxic threshold provides a direct pharmacological cause. Option C is identical in clinical meaning to option E but differs in phrasing; comparing the two — option C states the level "represents a toxic peak" while option E explicitly identifies the 100 mg/L threshold and the 5-FU-mediated mechanism — option E is the more complete and precise answer.
• Option D: Option D is incorrect because flucytosine can and should be safely restarted at a TDM-guided reduced dose after a brief hold; it is not permanently contraindicated in patients who develop cytopenias, and the cytopenias are concentration-dependent and reversible.

ANSWER: B

Rationale:

The treatment of cryptococcal meningitis follows a three-phase strategy: induction, consolidation, and maintenance. The induction phase — amphotericin B plus flucytosine for one to two weeks — aims to achieve CSF sterilization through maximal early fungicidal activity. Once CSF sterility is confirmed (as in this patient at day 14), the regimen transitions to consolidation: fluconazole 400 mg orally once daily for eight weeks, per WHO 2022 guidelines and standard international practice. Flucytosine is not continued into the consolidation or maintenance phases; its role is specifically in the induction period where its combination with amphotericin B achieves the rapid CSF sterilization that correlates with improved outcomes. Fluconazole consolidation is effective because it maintains adequate CSF drug concentrations to prevent regrowth of residual organisms while the patient's immune system begins reconstitution with antiretroviral therapy. Following consolidation, maintenance with fluconazole 200 mg daily is continued until CD4 count exceeds 200 cells/µL on stable antiretroviral therapy.

• Option A: Option A is incorrect because there is no guideline or clinical trial evidence supporting extended flucytosine use beyond the two-week induction phase; its myelosuppression risk during prolonged administration would outweigh any benefit not established by current evidence.
• Option C: Option C is incorrect because abrupt transition from amphotericin B combination induction to fluconazole consolidation is the standard and evidence-based approach; continuing amphotericin B and flucytosine for four additional weeks would increase nephrotoxicity and myelosuppression risks without established benefit after CSF sterilization.
• Option D: Option D is incorrect because indefinite maintenance flucytosine is not a guideline recommendation; maintenance therapy is fluconazole 200 mg daily until immune reconstitution, without flucytosine, and CD4 recovery on antiretroviral therapy does eventually allow safe discontinuation of maintenance antifungal prophylaxis.
• Option E: Option E is incorrect because itraconazole is not the guideline-preferred consolidation agent for cryptococcal meningitis; despite its lipophilicity and high brain tissue concentrations, clinical trial evidence supports fluconazole for this phase, and itraconazole has lower CSF concentrations than its brain parenchymal concentrations might suggest.

ANSWER: D

Rationale:

This patient presents a complex pharmacological challenge. Griseofulvin is a CYP3A4 and CYP1A2 inducer. Cyclosporine is a major CYP3A4 substrate — both its oral bioavailability and hepatic clearance depend substantially on CYP3A4 activity. Griseofulvin induction of CYP3A4 would increase cyclosporine metabolism, reducing trough concentrations below the therapeutic window of 100 to 150 ng/mL and placing the patient at risk of acute rejection of her transplanted kidney — a potentially catastrophic consequence. Simultaneously, griseofulvin induces CYP3A4-mediated warfarin metabolism, which would reduce the INR below the therapeutic range of 2.0 to 3.0 in a patient anticoagulated for an active venous thrombosis, increasing thromboembolic risk. These combined contraindications make griseofulvin a dangerous choice in this specific patient. Terbinafine inhibits CYP2D6 rather than inducing CYP3A4; it does not meaningfully affect cyclosporine or warfarin pharmacokinetics through CYP3A4, making it pharmacokinetically safer in this patient despite its lower clinical efficacy for M. canis compared to Trichophyton species. Specialist consultation regarding close monitoring, alternative agents, or deferral of treatment is appropriate.

• Option A: Option A is incorrect because terbinafine inhibits CYP2D6, not CYP3A4; cyclosporine is a CYP3A4 substrate, not a CYP2D6 substrate, so terbinafine does not meaningfully raise cyclosporine concentrations.
• Option B: Option B is incorrect because fluconazole is not the established first-line agent for M. canis tinea capitis, and fluconazole is a potent CYP3A4 inhibitor that would raise cyclosporine concentrations to potentially toxic levels — making it a significant interaction concern in transplant patients taking cyclosporine.
• Option C: Option C is incorrect because systemic antifungals have profoundly different interaction profiles with cyclosporine and warfarin; the claim that interaction risk is equivalent across all agents is pharmacologically inaccurate and could lead to serious patient harm if acted upon.
• Option E: Option E is incorrect because cyclosporine is extensively metabolized by CYP3A4 in both the intestinal wall and liver; it is not eliminated primarily by biliary excretion in a CYP3A4-independent manner, and CYP3A4 induction by griseofulvin substantially reduces cyclosporine exposure.

ANSWER: B

Rationale:

The stable cyclosporine trough and INR are the expected findings with terbinafine and correctly interpreted as confirmation that terbinafine does not meaningfully inhibit or induce CYP3A4 (the primary pathway for cyclosporine metabolism) or CYP2C9 (the primary pathway for S-warfarin metabolism). Terbinafine's relevant CYP interaction is selective, potent, and mechanism-based inhibition of CYP2D6. The resident's inference that terbinafine is "pharmacokinetically inert" is incorrect — it is highly pharmacokinetically active through CYP2D6, which metabolizes a broad range of clinically important drugs including tricyclic antidepressants, beta-blockers, many antipsychotics, codeine, tramadol, and others. A complete review of this patient's medication list for CYP2D6 substrates is warranted; if she takes any CYP2D6-metabolized drug, its dose may need adjustment or monitoring during terbinafine therapy.

• Option A: Option A is incorrect because terbinafine is not pharmacokinetically inert; it is a potent CYP2D6 inhibitor, and the absence of an interaction with CYP3A4 and CYP2C9 substrates does not imply the absence of interactions with CYP2D6 substrates.
• Option C: Option C is incorrect because cyclosporine does not induce P-glycoprotein in a way that counterbalances terbinafine's CYP2D6 inhibitory effect; this mechanism is fabricated and has no pharmacological basis.
• Option D: Option D is incorrect because terbinafine's CYP2D6 inhibition is mechanism-based and develops rapidly — within days to weeks as CYP2D6 enzyme is progressively inactivated — not after six to eight weeks; the stable cyclosporine and INR do not reflect a delayed effect but rather confirm that terbinafine genuinely does not affect CYP3A4 or CYP2C9.
• Option E: Option E is incorrect because the pharmacological reasoning is inverted; the absence of a terbinafine interaction with CYP3A4 does not imply that griseofulvin's CYP3A4 induction would also be negligible — the two drugs have entirely different mechanisms and enzyme interactions, and griseofulvin's CYP3A4 induction would have substantially lowered cyclosporine concentrations.

ANSWER: C

Rationale:

If the clinical decision is made to prescribe griseofulvin in this patient, active management of the cyclosporine interaction is mandatory. Griseofulvin induces CYP3A4 through nuclear receptor-mediated transcriptional upregulation; because cyclosporine is a major CYP3A4 substrate whose oral bioavailability and hepatic clearance are both CYP3A4-dependent, the induction effect will progressively lower cyclosporine trough concentrations over two to four weeks as induced enzyme reaches maximal activity. This risks acute rejection in a transplant patient whose immunosuppression is already at the lower end of the therapeutic window. The correct management approach requires: measuring cyclosporine troughs every one to two weeks after starting griseofulvin; anticipating the need for cyclosporine dose increases during the griseofulvin course; and planning a proactive cyclosporine dose reduction when griseofulvin is stopped, because induced CYP3A4 activity returns to baseline over two to four weeks following discontinuation, and if cyclosporine has been dose-escalated during griseofulvin treatment, the higher dose may produce toxic cyclosporine accumulation after griseofulvin is withdrawn.

• Option A: Option A is incorrect because cyclosporine does not produce significant CYP3A4 autoinduction; it is a substrate of CYP3A4, not an inducer, and there is no offsetting induction to cancel griseofulvin's CYP3A4 induction effect.
• Option B: Option B is incorrect because combining terbinafine and griseofulvin at half-doses for M. canis tinea capitis is not an established clinical regimen; there is no clinical trial evidence for this combination approach, and halving both drugs does not reliably eliminate the pharmacokinetic interaction risk from griseofulvin's CYP3A4 induction.
• Option D: Option D is incorrect because CYP3A4 induction by griseofulvin is a transcriptional effect mediated by nuclear receptor activation; while induction is driven by drug exposure, there is no established safe low-dose threshold at which griseofulvin induces CYP3A4 insufficiently to affect cyclosporine in a clinically meaningful way in a transplant patient.
• Option E: Option E is incorrect because griseofulvin is a CYP inducer (not inhibitor) and does not elevate the INR — it would lower the INR by increasing warfarin metabolism; cyclosporine does not have antithrombotic activity that would interact with warfarin; and the claim that the cyclosporine therapeutic range is wide enough to absorb CYP3A4 induction is incorrect for an agent this narrow in therapeutic index.

ANSWER: A

Rationale:

This case illustrates the critical pharmacokinetic principle that CYP enzyme induction is a transient, reversible process. When griseofulvin induces CYP3A4 transcription, the liver produces increased amounts of CYP3A4 enzyme protein. This increased enzyme pool accelerates cyclosporine metabolism, requiring the cyclosporine dose to be increased to maintain therapeutic troughs — which was correctly done here (150 → 225 mg twice daily). When griseofulvin is stopped, the inducing stimulus is removed; over the following two to four weeks, the elevated CYP3A4 enzyme pool gradually returns to the pre-induction baseline as induced enzyme is degraded and replaced by the normal constitutive enzyme level. During this transition, cyclosporine metabolism progressively slows. If the cyclosporine dose is not reduced as induction wanes, the drug accumulates — producing the supratherapeutic trough of 238 ng/mL and the clinical signs of cyclosporine toxicity: elevated creatinine from calcineurin inhibitor nephrotoxicity and tremor from neurotoxicity. Prompt cyclosporine dose reduction toward the original 150 mg twice daily with close trough monitoring is the correct management. This bidirectional requirement — dose increase when the inducer is added and dose reduction when it is stopped — is a universal principle that applies whenever any CYP inducer is added to or removed from a regimen containing a CYP substrate with a narrow therapeutic index.

• Option B: Option B is incorrect because CYP3A4 induction by griseofulvin is not permanent; it is driven by ongoing nuclear receptor activation by the drug, which ceases when griseofulvin is eliminated. Epigenetic CYP3A4 methylation causing permanent transcriptional upregulation after drug withdrawal is not an established pharmacological mechanism.
• Option C: Option C is incorrect because griseofulvin does not produce residual metabolites that persist for six to eight weeks and convert from inducers to CYP3A4 inhibitors; once griseofulvin and its metabolites are eliminated, CYP3A4 activity returns to baseline through normal enzyme protein turnover.
• Option D: Option D is incorrect because griseofulvin is a CYP3A4 inducer, not a mechanism-based irreversible inhibitor; the distinction between induction (reversible transcriptional upregulation) and mechanism-based inhibition (irreversible covalent inactivation) is fundamental, and CYP3A4 induction is fully reversible.
• Option E: Option E is incorrect because griseofulvin does not generate a nephrotoxic cyclosporine metabolite through CYP1A2 induction, and the supratherapeutic cyclosporine trough directly explains the nephrotoxicity through calcineurin inhibitor toxicity rather than through a separately generated metabolite.

ANSWER: A

Rationale:

When amphotericin B is unavailable, the WHO 2022 guidelines for cryptococcal disease recommend oral fluconazole 1200 mg once daily combined with flucytosine 25 mg/kg every 6 hours for two weeks of induction as the preferred alternative regimen. This recommendation is directly supported by the ACTA (Advancing Cryptococcal Meningitis Treatment for Africa) trial, which compared four induction regimens in a randomized controlled design in sub-Saharan Africa. The trial demonstrated that the fluconazole plus flucytosine arm achieved faster CSF sterilization (higher early fungicidal activity at day 7 and day 14) and significantly reduced 10-week mortality compared to fluconazole monotherapy at 800 mg, establishing the combination as superior to high-dose fluconazole alone. The pharmacological rationale is complementary mechanism coverage: fluconazole inhibits ergosterol synthesis via CYP51 while flucytosine provides an antimetabolite mechanism targeting nucleic acid synthesis, and both agents achieve excellent CSF penetration.

• Option B: Option B is incorrect because flucytosine monotherapy for cryptococcal meningitis or any serious fungal infection is never appropriate; primary resistance exists in some isolates, secondary resistance emerges rapidly with single-agent use, and no clinical trial supports flucytosine alone as an induction regimen.
• Option C: Option C is incorrect because trimethoprim-sulfamethoxazole has no established antifungal activity against Cryptococcus neoformans; it inhibits bacterial dihydropteroate synthase and dihydrofolate reductase but does not produce clinically meaningful antifungal efficacy against Cryptococcus at any dose.
• Option D: Option D is incorrect because high-dose fluconazole 800 mg monotherapy is not the WHO 2022 first-line recommendation when amphotericin B and flucytosine are both unavailable — the fluconazole plus flucytosine combination is preferred when flucytosine is available; fluconazole 800 mg monotherapy is reserved for settings where both amphotericin B and flucytosine are unavailable.
• Option E: Option E is incorrect because trimethoprim-sulfamethoxazole has no clinically relevant antifungal activity against Cryptococcus neoformans; its folate-inhibiting mechanism is effective against bacteria and Pneumocystis jirovecii but not against Cryptococcus, and this combination is not an evidence-based cryptococcal meningitis regimen.

ANSWER: E

Rationale:

Standard flucytosine renal dose-adjustment tables specify that when CrCl falls to 25 to 50 mL/min, the dosing interval should be extended from every 6 hours to every 12 hours while maintaining the per-dose amount at 25 mg/kg. This interval extension reduces total daily drug delivery while preserving per-dose concentration to maintain adequate peak levels for antifungal activity, targeting a balance between efficacy and reduced accumulation risk. At an estimated CrCl of 38 mL/min, this bracket applies and extending to twice-daily dosing is the appropriate table-based adjustment when TDM is unavailable. In resource-limited settings where flucytosine drug level measurement is not available, clinical and CBC-based monitoring provides a surrogate indicator of toxicity: a falling WBC or platelet count in temporal relation to flucytosine therapy signals potential supratherapeutic exposure requiring further dose or interval adjustment.

• Option A: Option A is incorrect because a CrCl of 38 mL/min reflects a clinically meaningful reduction in glomerular filtration that directly impairs flucytosine clearance; regardless of the etiology (volume depletion vs. intrinsic renal injury), the measured or estimated CrCl determines flucytosine clearance and the dose adjustment requirement.
• Option B: Option B is incorrect because flucytosine can be safely continued with interval adjustment at a CrCl of 38 mL/min; the drug is not absolutely contraindicated above a creatinine threshold of 1.5 mg/dL, and removing it from the regimen would eliminate the combination's proven benefit over fluconazole monotherapy.
• Option C: Option C is incorrect because the standard renal adjustment for flucytosine is interval extension rather than dose reduction; maintaining the per-dose amount while extending the interval is the recommended approach in the CrCl 25 to 50 mL/min range, not halving the per-dose amount and keeping the interval unchanged.
• Option D: Option D is incorrect because increasing the flucytosine dose in a patient with reduced renal clearance is pharmacokinetically dangerous and directly contraindicated; increased volume of distribution in sepsis does not justify dose escalation for a drug that is already accumulating due to impaired renal elimination.

ANSWER: B

Rationale:

Flucytosine's failure as monotherapy is not a pharmacokinetic limitation but a microbiological inevitability rooted in population genetics. Every large fungal population contains a small number of cells that carry pre-existing mutations in the three-step flucytosine activation pathway: loss-of-function mutations in cytosine permease (preventing cellular uptake), cytosine deaminase (preventing conversion to 5-FU), or URA3/URA5 enzymes (preventing conversion of 5-FU to the active nucleotides FdUMP and FUTP). These resistant mutants are present before any drug exposure; they are not created by the drug. When flucytosine is used as monotherapy, it rapidly kills the susceptible majority while applying selection pressure that allows the pre-existing resistant minority to survive and proliferate. In a patient with a CSF cryptococcal antigen titer of 1:2048 — reflecting an enormous fungal burden — the absolute number of pre-existing resistant mutants is large, and resistance clinically emerges within days. Combination with amphotericin B or fluconazole reduces resistance emergence by rapidly decreasing the total fungal burden (reducing the absolute number of resistant cells available for selection) while adding an independent antifungal mechanism that does not share resistance pathways with flucytosine.

• Option A: Option A is incorrect because flucytosine has excellent intrinsic CSF penetration (70–85% of plasma concentrations) that is pharmacokinetically independent and does not require facilitation by a second agent disrupting blood-brain barrier tight junctions; this mechanism is fabricated.
• Option C: Option C is incorrect because Cryptococcus neoformans does not produce a beta-glucan synthase-mediated inactivating derivative of flucytosine; no such self-inactivation pathway exists.
• Option D: Option D is incorrect because the primary flucytosine resistance mechanism in Cryptococcus neoformans is mutations in the intracellular activation pathway (cytosine permease, cytosine deaminase, URA enzymes), not constitutive overexpression of P-glycoprotein efflux pumps; P-glycoprotein efflux is the dominant resistance mechanism for azoles, not for flucytosine.
• Option E: Option E is incorrect because flucytosine's antimetabolite mechanism targets proliferating cells through DNA and RNA synthesis disruption, but Cryptococcus neoformans in CSF is not primarily in a stationary growth phase that renders the drug ineffective; the basis for combination requirement is resistance emergence, not growth-phase-dependent drug activity.

ANSWER: D

Rationale:

Following successful induction with CSF sterilization at day 14, the correct transition is to consolidation therapy: fluconazole 400 mg orally once daily for eight weeks, per WHO 2022 guidelines and international practice. Flucytosine is not continued into consolidation; its role was specifically in the induction phase where the combination with fluconazole achieved rapid CSF sterilization. The evidence for the timing of ART initiation comes from the COAT (Cryptococcal Optimal ART Timing) trial and subsequent analyses, which demonstrated that immediate ART initiation in cryptococcal meningitis is associated with increased mortality, predominantly due to cryptococcal IRIS — a paradoxical immune reconstitution inflammatory syndrome triggered by recovering immune function attacking residual cryptococcal antigen. The risk is highest in patients with high fungal burden, as reflected by high cryptococcal antigen titers (this patient had 1:2048). Current guidelines recommend deferring ART until approximately four to six weeks after antifungal induction is started, allowing time for fungal burden reduction before immune reconstitution is initiated. Following consolidation, maintenance with fluconazole 200 mg daily is continued until CD4 exceeds 200 cells/µL on stable ART.

• Option A: Option A is incorrect because successful CSF sterilization at day 14 is the transition criterion to consolidation; the oral combination induction does not require a longer induction duration than amphotericin B-based regimens simply because of its agent composition — outcome data from the ACTA trial demonstrate two-week induction endpoints for both regimen types.
• Option B: Option B is incorrect because immediate ART at day 14 is not recommended in cryptococcal meningitis; the COAT trial demonstrated increased mortality with immediate ART compared to deferred ART, and this patient's very high initial antigen titer places him at high IRIS risk. Option C and Option D convey similar clinical content (consolidation + deferred ART at 4–6 weeks); Option D is more pharmacologically complete because it explicitly notes that flucytosine is not continued and specifically names the IRIS risk in the context of this patient's high antigen titer, making it the more complete and precise answer.
• Option E: Option E is incorrect because flucytosine is never used as a consolidation agent and should never be used as monotherapy; the consolidation phase uses fluconazole alone, and flucytosine's antimetabolite mechanism is not the rationale for its use — combination combination coverage during active induction is.

ANSWER: C

Rationale:

This patient presents with symptomatic terbinafine-associated hepatotoxicity. The clinical picture — jaundice, right upper quadrant discomfort, and fatigue — combined with biochemical hepatitis (ALT 4.8×ULN, AST 3.6×ULN) occurring in temporal relation to terbinafine administration after seven weeks of therapy represents a classic presentation of terbinafine idiosyncratic hepatotoxicity. Current prescribing guidance from regulatory authorities and product labeling specifies that terbinafine should be discontinued immediately when ALT or AST rises above 3 times ULN in the presence of symptoms. This patient has symptoms (jaundice, RUQ pain, fatigue) and an ALT of 4.8×ULN — both meeting and exceeding the symptomatic threshold. The mechanism is idiosyncratic and immune-mediated, meaning continuation at any dose risks progression to fulminant hepatic failure or cholestatic hepatitis that may take months to resolve. Prompt discontinuation is the single most important intervention. A physician should not wait for specific numeric thresholds beyond what the guidance specifies — a symptomatic patient with hepatitis above the threshold must stop the drug.

• Option A: Option A is incorrect because terbinafine is associated with hepatotoxicity independent of its classification as a non-azole; its idiosyncratic hepatic injury is well documented and does not require pre-existing fatty liver disease to occur.
• Option B: Option B is incorrect because terbinafine can cause cholestatic as well as hepatocellular patterns of liver injury; the elevated alkaline phosphatase here is entirely consistent with terbinafine-associated mixed hepatocellular-cholestatic injury rather than implying a biliary stone as an alternative diagnosis requiring continuation of the drug.
• Option D: Option D is incorrect because the stopping threshold for symptomatic terbinafine hepatotoxicity is ALT or AST above 3 times ULN with symptoms — not 10 times ULN — and dose reduction in idiosyncratic immune-mediated hepatotoxicity does not reduce the immunological injury mechanism.
• Option E: Option E is incorrect because terbinafine should not be continued while awaiting liver biopsy histology; the clinical and biochemical evidence already meets the stopping criteria, and further drug exposure in a patient with symptomatic hepatitis risks serious and potentially irreversible harm.

ANSWER: D

Rationale:

The mechanism of terbinafine hepatotoxicity is idiosyncratic and appears to be immune-mediated rather than dose-dependent. The evidence for an immune-mediated mechanism includes: the unpredictable timing and low incidence across a large treated population (approximately 1 in 50,000 to 1 in 120,000), the inability to predict or prevent injury through dose adjustment, the presence of histological features consistent with immune-mediated injury in documented cases, and the clinical pattern of injury appearing weeks into therapy rather than immediately upon starting. In immune-mediated drug reactions, the drug or its reactive metabolites act as haptens or direct immunogens, triggering T-cell-mediated or antibody-dependent hepatocellular injury. When the offending drug is removed, the antigenic stimulus is eliminated and the immune response gradually resolves; injured hepatocytes are cleared and replaced through hepatocyte proliferation and regeneration. The time course of six weeks for normalization is consistent with this mechanism — immune-mediated hepatitis resolves over weeks to months after drug withdrawal.

• Option A: Option A is incorrect because terbinafine's plasma half-life does not govern recovery from idiosyncratic immune-mediated hepatotoxicity; plasma clearance and tissue distribution are distinct from the duration of immune injury, which resolves on an immune-biology time course rather than a pharmacokinetic one.
• Option B: Option B is incorrect because terbinafine hepatotoxicity is not dose-dependent and does not resolve through a cumulative-dose threshold mechanism; it is idiosyncratic, occurring at standard therapeutic doses in susceptible individuals, and the injury mechanism is immunological rather than pharmacotoxicological in the traditional sense.
• Option C: Option C is incorrect because CYP2D6 inactivation by terbinafine occurs in hepatocytes but is not the cause of hepatotoxicity; the hepatotoxicity is a separate idiosyncratic injury process unrelated to CYP2D6 enzyme status, and recovery does not require complete hepatocyte replacement.
• Option E: Option E is incorrect because while the hapten concept has been proposed for some drug-induced liver injuries, terbinafine does not form stable covalent adducts with albumin that hydrolyze within 72 hours; resolution takes weeks, not 72 hours, which is inconsistent with an instantaneously reversible adduct mechanism.

ANSWER: A

Rationale:

Re-challenge with a drug that has caused idiosyncratic immune-mediated hepatotoxicity is generally contraindicated in clinical practice. The concern is that a re-exposed patient may mount a more rapid and more severe immune response because of prior sensitization — anamnestic immunological memory — resulting in recurrent hepatitis that may be more fulminant than the original episode. Cases of fatal hepatic failure on re-challenge with terbinafine after prior idiosyncratic hepatotoxicity have been reported. The fact that liver tests have normalized does not restore safety; normalization reflects recovery from injury, not elimination of immune susceptibility to the drug. For this patient's onychomycosis, itraconazole is an effective systemic alternative for Trichophyton rubrum with a different structural class and different hepatotoxicity profile; it does not share terbinafine's specific idiosyncratic mechanism, though itraconazole carries its own hepatotoxicity risk that is distinct in mechanism and clinical presentation.

• Option B: Option B is incorrect because dose reduction does not mitigate idiosyncratic immune-mediated hepatotoxicity risk; the reaction is not dose-dependent and occurs through an immune mechanism that is not predictably reducible by halving the dose.
• Option C: Option C is incorrect because terbinafine hepatotoxicity is not caused by CYP2D6 poor metabolizer status leading to drug accumulation; it is idiosyncratic and immune-mediated, not a pharmacokinetic accumulation phenomenon, so CYP2D6 genotyping does not predict or exclude hepatotoxicity risk.
• Option D: Option D is incorrect because idiosyncratic drug hepatotoxicity reactions are characteristically antigen-specific — the offending drug or its reactive metabolites are the specific immune trigger — and re-challenge commonly produces faster and more severe recurrent injury precisely because the immune response is sensitized and antigen-specific.
• Option E: Option E is incorrect because graded desensitization protocols have limited applicability to idiosyncratic hepatotoxicity; unlike IgE-mediated anaphylaxis (where tolerance can be induced through antigen titration), cell-mediated idiosyncratic hepatotoxicity does not have an established safe desensitization protocol, and this approach is not validated or recommended.

ANSWER: E

Rationale:

Current prescribing guidance balances the rare but serious risk of terbinafine hepatotoxicity against the practical reality of monitoring a cosmetically motivated treatment in a large population. Baseline LFTs are recommended — though not universally mandated in all prescribing environments — in patients with pre-existing liver disease (hepatitis, cirrhosis, non-alcoholic steatohepatitis) or significant alcohol use, who represent a higher-risk subgroup. All patients should receive explicit counseling about hepatotoxicity warning symptoms (jaundice, dark urine, right upper quadrant pain, fatigue) and instructed to seek immediate assessment if these develop, because the idiosyncratic mechanism means that symptom reporting is more sensitive for early detection than fixed monitoring schedules in low-risk patients. The estimated incidence of serious liver injury is approximately 1 in 50,000 to 1 in 120,000 treated patients — making it rare enough that universal routine weekly monitoring is not standard practice, yet significant enough in absolute numbers to warrant appropriate risk communication given the large volume of onychomycosis prescribing.

• Option A: Option A is incorrect because the incidence of serious terbinafine hepatotoxicity is approximately 1 in 50,000 to 1 in 120,000, not approximately 5%; the 5% figure dramatically overstates the risk and would misrepresent the drug's safety profile to patients.
• Option B: Option B is incorrect because while routine monitoring of all patients is not standard, pre-treatment baseline LFTs are recommended in high-risk patients, and patients should be counseled about hepatotoxicity symptoms — the statement that monitoring is both unhelpful and not recommended is incorrect.
• Option C: Option C is incorrect because terbinafine is not absolutely contraindicated in all patients with any liver disease; pre-existing liver disease warrants caution and baseline monitoring but is not categorically an absolute contraindication, and the proposed workup (biopsy, fibroscan in all patients) is disproportionate to the clinical situation.
• Option D: Option D is incorrect because weekly LFT monitoring throughout the 12-week course is not the standard recommendation; the monitoring approach for most patients relies on symptom-triggered assessment rather than fixed weekly biochemical testing, with closer surveillance reserved for high-risk patients.

ANSWER: B

Rationale:

This is a classic presentation of an acute hepatic porphyria attack — in this case precipitated by griseofulvin in a patient with previously undiagnosed latent porphyria. The clinical features — severe abdominal pain, neuropsychiatric symptoms (confusion), motor neuropathy (leg weakness), autonomic dysfunction (hypertension), hyponatremia from SIADH, dark urine, and markedly elevated urine porphobilinogen — collectively constitute the diagnostic triad and associated features of an acute porphyric attack. The precipitant is griseofulvin, which induces hepatic ALA-S1 (delta-aminolevulinic acid synthase), the rate-limiting enzyme of heme biosynthesis; in this patient's latent porphyria, a downstream enzymatic defect prevents normal processing of the increased porphyrin precursor flux, leading to toxic accumulation of ALA and PBG. Immediate management requires: (1) discontinuing the precipitating drug (griseofulvin) without delay; (2) administering IV hemin (haem arginate), which directly suppresses ALA-S1 transcription through heme feedback inhibition and is the most effective acute treatment; (3) high-carbohydrate loading (glucose infusion) to further suppress ALA-S1 through insulin-mediated pathway suppression; (4) close monitoring for respiratory compromise from progressive motor neuropathy, which may require ventilatory support; and (5) pain management and correction of metabolic disturbances including hyponatremia.

• Option A: Option A is incorrect because continuing griseofulvin in an established acute porphyric attack would perpetuate ALA-S1 induction and worsen the attack; the drug must be stopped immediately and tinea capitis treatment deferred.
• Option C: Option C is incorrect because corticosteroids are not the treatment for acute porphyria; they may worsen the attack by increasing heme demand and can be porphyrinogenic themselves; IV hemin and glucose loading are the evidence-based acute interventions.
• Option D: Option D is incorrect because by the time an acute attack has developed — three weeks into griseofulvin therapy — drug absorption is complete and gastrointestinal decontamination with activated charcoal has no role; hemin therapy is necessary for a severe attack with motor involvement and neuropsychiatric features.
• Option E: Option E is incorrect because this presentation is not serotonin syndrome — which characteristically presents with clonus, hyperreflexia, hyperthermia, agitation, and diarrhea rather than the abdominal pain, motor neuropathy, dark urine, and elevated PBG seen here; urine PBG elevation is diagnostic of porphyria, not a non-specific inflammatory finding.

ANSWER: A

Rationale:

This question teaches the fundamental pharmacogenetic mechanism of drug-triggered acute porphyric attacks. Patients with acute intermittent porphyria carry a heterozygous loss-of-function mutation in HMBS — the gene encoding hydroxymethylbilane synthase (porphobilinogen deaminase), the third enzyme of the heme biosynthesis pathway. Because they have one functional copy of the gene, residual HMBS activity is approximately 50% of normal. Under baseline conditions, this reduced capacity is usually sufficient to process the basal flux of porphyrin precursors without toxic accumulation, explaining why carriers are often asymptomatic for decades. Griseofulvin induces hepatic ALA-S1, the rate-limiting and first committed enzyme of heme synthesis; this induction substantially increases the rate of production of ALA and PBG upstream of the defective HMBS step. In a normal individual, the induced ALA-S1 flux is processed without difficulty because all downstream enzymatic steps have adequate capacity. In this patient with approximately 50% HMBS activity, the increased precursor flux induced by griseofulvin exceeds the reduced enzymatic processing capacity at the HMBS step; ALA and PBG accumulate to toxic concentrations in the liver, spill into the circulation, and produce the systemic manifestations of an acute attack. The 31 years of clinical silence reflects the adequacy of residual HMBS capacity under baseline conditions — griseofulvin provided the precipitating pharmacological stress that unmasked the latent vulnerability.

• Option B: Option B is incorrect because acute porphyric attacks are not caused by somatic mutations acquired during drug therapy; the underlying genetic defect is germline, inherited, and present from birth — the attack reflects a pharmacological precipitant, not a new genetic event.
• Option C: Option C is incorrect because griseofulvin's CYP3A4 induction does not suppress heme degradation to produce positive feedback on ALA-S1; the mechanism by which griseofulvin induces ALA-S1 is through nuclear receptor activation of ALA-S1 gene transcription, not through heme feedback loop manipulation.
• Option D: Option D is incorrect because griseofulvin does not directly inhibit HMBS enzyme activity; it does not bind the HMBS enzyme competitively, and the mechanism is ALA-S1 induction increasing substrate flux, not direct downstream enzyme inhibition.
• Option E: Option E is incorrect because carbohydrate restriction does not constitutively suppress ALA-S1 through an insulin-independent mechanism that griseofulvin then removes; carbohydrate loading is used therapeutically to suppress ALA-S1 activity during an attack, but dietary carbohydrate intake was not the variable that destabilized this patient.

ANSWER: D

Rationale:

In a patient with confirmed acute intermittent porphyria, selecting a systemic antifungal requires excluding any agent that induces ALA-S1 or otherwise stimulates heme biosynthesis. Griseofulvin is absolutely contraindicated — it is the cause of the current attack. Terbinafine inhibits squalene epoxidase in the ergosterol biosynthesis pathway; it does not induce ALA-S1, does not activate nuclear receptors that upregulate heme synthesis genes, and is not listed among porphyrinogenic drugs in porphyria drug databases. While terbinafine achieves lower mycological cure rates for Microsporum canis tinea capitis than for Trichophyton species (as established in comparative trials), the pharmacological safety consideration in an AIP patient takes precedence over the comparative efficacy disadvantage. Terbinafine is therefore the preferred systemic agent for this patient's M. canis tinea capitis, with the understanding that response rates may be lower and clinical follow-up for mycological cure confirmation is important. Azole antifungals (fluconazole, itraconazole) are also generally considered safer than griseofulvin for porphyria patients and can be considered as alternative options, though not all azoles have equivalent safety data in AIP.

• Option A: Option A is incorrect because there is no established safe low dose of griseofulvin for AIP patients; griseofulvin's porphyrinogenic mechanism is transcriptional ALA-S1 induction, and any degree of ALA-S1 induction in a patient with partial HMBS activity risks precipitating another attack — a dose threshold guaranteeing safety has not been established.
• Option B: Option B is incorrect because fluconazole and other azoles are not generally contraindicated in AIP through a porphyrinogenic CYP51-heme catabolism mechanism; this mechanistic claim is inaccurate, and azoles are generally considered lower-risk options than griseofulvin for AIP patients.
• Option C: Option C is incorrect because not all systemic antifungals are equally contraindicated in AIP; the porphyrinogenic classification is drug-specific, and terbinafine is an example of a systemic antifungal that can be used.
• Option E: Option E is incorrect because flucytosine combined with fluconazole is not an established treatment for M. canis tinea capitis and is not part of any AIP tinea capitis management guidelines; flucytosine's indication is systemic fungal infections (cryptococcal meningitis, selected Candida infections), not dermatophyte skin and hair infections.

ANSWER: C

Rationale:

Acute intermittent porphyria is an autosomal dominant disorder caused by heterozygous loss-of-function mutations in the HMBS gene. First-degree relatives of an affected individual have a 50% probability of carrying the same pathogenic variant. Critically, most carriers — estimated at 80 to 90% — remain asymptomatic throughout their lives despite carrying the mutation; the low penetrance means that carrier status alone does not guarantee clinical disease. However, carriers are at risk of precipitated acute attacks when exposed to porphyrinogenic drugs, fasting, hormonal changes, infection, or other triggers. Genetic counseling and targeted mutation testing for the confirmed pathogenic HMBS variant identified in the proband is the appropriate first step for first-degree relatives. If the sister is found to carry the mutation, she should: receive a comprehensive list of porphyrinogenic drugs to avoid (including griseofulvin, barbiturates, sulfonamides, estrogen-containing preparations, certain anticonvulsants); carry medical alert documentation; and receive education about other triggers including caloric restriction and alcohol. This proactive approach can prevent iatrogenic acute attacks.

• Option A: Option A is incorrect because AIP is autosomal dominant, not recessive; a heterozygous pathogenic HMBS mutation is sufficient to confer risk of acute attacks, and first-degree relatives have a 50% chance of inheriting the same variant.
• Option B: Option B is incorrect because empiric drug avoidance without genetic testing deprives the sister of the information she needs to make informed decisions; if she does not carry the mutation, unnecessary drug restrictions impose unwarranted limitations, and genetic testing provides certainty.
• Option D: Option D is incorrect because prophylactic monthly IV hemin is not recommended for asymptomatic carriers of AIP; hemin therapy is used for acute attacks and in a small subset of patients with recurrent attacks (in conjunction with specialist hematology guidance), not as universal prophylaxis for all carriers.
• Option E: Option E is incorrect because baseline urine PBG levels are unreliable for identifying asymptomatic carriers; most asymptomatic AIP carriers have normal or only mildly elevated PBG at baseline because the enzymatic deficiency is compensated under non-challenged conditions — only genetic testing reliably identifies carrier status.

ANSWER: E

Rationale:

At 52 kg, this patient falls in the above-40 kg weight bracket for terbinafine pediatric dosing, meaning the adult dose of 250 mg once daily applies. Terbinafine is appropriate and has been used in pediatric tinea capitis. However, the species-specific consideration is critical: comparative trials demonstrate that terbinafine achieves lower mycological cure rates for Microsporum canis tinea capitis than for Trichophyton tonsurans tinea capitis, while griseofulvin maintains more consistent efficacy against Microsporum species. Griseofulvin microsize dosed at 20 to 25 mg/kg/day remains a guideline-accepted first-line option for M. canis tinea capitis, particularly in pediatric and adolescent patients where it has the longest established safety and efficacy record for this organism. The correct approach acknowledges both agents as valid options, with the understanding that griseofulvin may have superior M. canis efficacy and terbinafine (while pharmacokinetically appropriate at 250 mg) carries lower cure rates for this species. Options D and E are closely related; option E is the more complete answer because it explicitly acknowledges the dosing rationale (weight-based bracket) and identifies the species-specific efficacy difference as the key decision factor, and frames the choice as an evidence-informed shared decision rather than a categorical preference.

• Option A: Option A is incorrect because fluconazole is not the first-line established treatment for M. canis tinea capitis; while it has been used off-label, it is not the standard recommended agent, and the claim of superior hair follicle penetration compared to terbinafine and griseofulvin overstates the evidence.
• Option B: Option B is incorrect because the 125 mg pediatric terbinafine dose applies to the 20 to 40 kg weight bracket; at 52 kg, this patient is in the above-40 kg bracket and the 250 mg adult dose is appropriate — using a lower dose because of age rather than weight ignores the established weight-bracket dosing framework.
• Option C: Option C is incorrect because terbinafine does have regulatory approval and established pediatric dosing for tinea capitis in most major jurisdictions, and the claim that it is not approved under age 18 is inaccurate.
• Option D: Option D is incorrect because griseofulvin is not contraindicated in adolescent patients on the basis of gonadotoxicity; it is contraindicated in pregnancy and porphyria, but no blanket contraindication for patients under 18 years based on gonadotoxicity is established, and griseofulvin is in fact used in pediatric and adolescent tinea capitis as a guideline-supported option for Microsporum species.

ANSWER: C

Rationale:

Griseofulvin is an inducer of CYP3A4 (cytochrome P450 3A4) and CYP1A2. Ethinylestradiol, the estrogenic component of combined oral contraceptives, is metabolized substantially by CYP3A4. When griseofulvin induces CYP3A4, the rate of ethinylestradiol metabolism increases, reducing its plasma concentrations. If ethinylestradiol concentrations fall below the threshold required to suppress the LH surge and inhibit ovulation, contraceptive failure may result. This interaction is well documented and cases of unintended pregnancy during griseofulvin therapy have been reported. The counseling requirement is explicit: additional barrier contraception (such as condoms) must be used during the entire griseofulvin course and for at least one month after the last dose, because CYP3A4 induction persists for two to four weeks after griseofulvin discontinuation as induced enzyme protein is gradually degraded and replaced by the constitutive baseline level. The hormonal contraceptive should not be stopped — the patient still needs contraception — but must be supplemented with barrier methods. The prescriber should also note that griseofulvin's induction of CYP3A4 and CYP1A2 may affect the progestin component as well.

• Option A: Option A is incorrect because ethinylestradiol is metabolized by CYP3A4, not exclusively by CYP2C9; griseofulvin induces CYP3A4 and the interaction is established and clinically significant.
• Option B: Option B is incorrect because griseofulvin is a CYP3A4 inducer, not an inhibitor; enzyme induction would reduce (not increase) ethinylestradiol concentrations, risking contraceptive failure rather than estrogen toxicity.
• Option D: Option D is incorrect because CYP3A4 induction is a transcriptional mechanism requiring new protein synthesis over days to weeks; it is not a contact-dependent interaction at the intestinal mucosa that can be avoided by timing the dose separation, and separating administration by 4 hours has no effect on the enzymatic induction phenomenon.
• Option E: Option E is incorrect because both ethinylestradiol and progestin components of combined OCs are metabolized by CYP3A4 and subject to griseofulvin's induction; claiming that ethinylestradiol provides backup suppression when levonorgestrel levels fall misunderstands the pharmacology and the established clinical risk of this interaction.

ANSWER: B

Rationale:

Griseofulvin's mechanism of action in tinea capitis is intimately linked to keratin deposition kinetics. After oral administration, griseofulvin is absorbed and distributed systemically, but its therapeutic effect depends on its selective accumulation and retention in newly formed keratinized cells — the stratum corneum, hair, and nails. As the hair follicle produces new keratin cells, they incorporate griseofulvin from the systemic circulation; the drug-containing new keratin then grows outward along the hair shaft. In tinea capitis, dermatophytes invade the hair shaft and the surrounding follicular epithelium; clinical cure requires that the infected, drug-free keratin be fully displaced and replaced by drug-containing new keratin that inhibits dermatophyte invasion during outgrowth. This process takes time governed by hair growth kinetics — approximately 1 cm per month. Stopping griseofulvin at four weeks when clinical improvement is apparent but full keratin replacement is incomplete leaves a zone of infected keratin partway along the hair shaft that still contains viable organisms. New drug-free keratin produced after stopping the drug is susceptible to recolonization, and relapse occurs. A minimum of six to eight weeks is required for tinea capitis to ensure sufficient drug-containing keratin replaces the infected hair along its full length.

• Option A: Option A is incorrect because griseofulvin's pharmacodynamic activity is not classified as concentration-dependent in the same way as aminoglycoside antibiotics; the treatment duration requirement is based on keratin replacement kinetics rather than on maintaining MIC thresholds above a trough level.
• Option C: Option C is incorrect because steady-state distribution in follicular epithelium is achieved within days to weeks after initiating treatment, not at exactly four weeks; the reason for continuing beyond four weeks is keratin outgrowth completion, not delayed distribution to follicular targets.
• Option D: Option D is incorrect because griseofulvin has fungistatic activity against dermatophytes in general, but the duration requirement for tinea capitis treatment is driven by the time needed for infected keratin to be physically replaced by drug-containing new keratin, not by the time needed for immune-mediated clearance of suppressed organisms.
• Option E: Option E is incorrect because griseofulvin does not undergo clinically significant enterohepatic recycling that creates a prolonged release mechanism governing follicular concentrations; its absorption is fat-dependent, and the pharmacokinetic basis for treatment duration is keratinophilic tissue deposition and outgrowth, not recycling.

ANSWER: D

Rationale:

Griseofulvin microsize formulation has highly variable oral bioavailability — ranging from approximately 25 to 70% — that is critically dependent on the presence of dietary fat during co-administration. Dietary fat produces two effects that are essential for griseofulvin absorption: it stimulates the release of bile acids from the gallbladder into the intestinal lumen, and it increases the lipid content of the intestinal environment. Together, these effects solubilize griseofulvin's lipophilic particles in bile acid micelles, enabling them to partition from the solid phase into a solubilized form that can be absorbed across the intestinal mucosa. When griseofulvin is taken on an empty stomach with only water — as this patient has been doing — the bile acid response is minimal and the intestinal lipid content is essentially zero; the drug particles cannot be adequately solubilized and absorption is dramatically reduced. This is the explanation for the subtherapeutic serum levels and the treatment failure. The correct intervention is straightforward patient education: the patient must take griseofulvin with a meal containing a meaningful amount of fat — whole milk, full-fat yogurt, peanut butter on toast, eggs, or any substantial fat-containing food. The ultramicrosize formulation (Gris-PEG) is less critically fat-dependent due to its smaller particle size and polyethylene glycol dispersion, but the prescribed microsize formulation requires fat co-administration for therapeutic bioavailability.

• Option A: Option A is incorrect because griseofulvin's primary absorption limitation is lipid solubility rather than P-glycoprotein efflux; P-gp is more relevant to drugs with high aqueous solubility that are substrates for active intestinal efflux, not to lipophilic drugs whose absorption is primarily solubilization-limited.
• Option B: Option B is incorrect because griseofulvin absorption does not require gastric acid for dissolution and is not enhanced by proton pump inhibitor co-administration; the limiting factor is lipid-mediated solubilization in the intestinal lumen, not pH-dependent dissolution in the stomach.
• Option C: Option C is incorrect because griseofulvin is not absorbed through a saturable active transporter in competition with glucose; it is absorbed by passive diffusion once solubilized in the intestinal lipid-bile acid microenvironment, and glucose competition with an active transporter is not an established mechanism for griseofulvin absorption.
• Option E: Option E is incorrect because the volume of water co-administered does not impair griseofulvin absorption through bile acid dilution; the critical variable is dietary fat, not fluid volume, and restricting fluid intake to 50 mL would not improve absorption in the absence of dietary fat.